Co-targeting ASAH1 and the histone reader BRD1 potently suppresses TNBC growth through the transcriptional repressor BCL6
A previously undocumented therapeutic combination of BRD1 inhibitors and ASAH1 inhibitor carmofur is identified as a promising treatment strategy for triple-negative breast cancer.